KeyBanc analyst Matthew Mishan reiterated an Overweight rating on Becton Dickinson but lowered his price target to $262 from $273, saying investor expectations appear to have been subdued going into the Q2 report, and while it wasn't the most positive quarter or guidance update, Becton's value proposition is still mostly unchanged. Mishan tells investors in a research note that he remains comfortable with a ~5% organic growth profile, even with the paclitaxel situation and said that while the loss of the Gore Royalty will replace some of the current transitory EPS headwinds, margin expansion may be more visible in FY20.